Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Step-Up IBD Therapy for Hermansky-Pudlak Syndrome-Associated Colitis
NCT00514982Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2007
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Salcrozine, prednisone, infliximab, mercaptopurine, adalimumab and 1 more in Colitis, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Patterns of immune abnormalities in the colitis associated with Hermansky-Pudlak Syndrome at 60 weeks. Planned start Aug 2007; status: withdrawn.
02
Drugs
03
Conditions
Colitis
Beyond the preview
Go deeper on NCT00514982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514982.